Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.
Tag: ASH20
Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma
Older individuals are at an increased risk of developing primary central nervous system lymphoma (PCNSL). In a retrospective study of patients with newly diagnosed PCNSL, researchers at Rutgers Cancer Institute of New Jersey and colleagues used geriatric assessments to analyze detailed characteristics, treatment, and outcomes in patients across 17 academic centers.
Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2
Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.
New Biomarker Identifies Patients with Aggressive Lymphoma Who Don’t Respond to Precision Therapy
A new biomarker discovered by a team that includes researchers from Penn Medicine identifies patients with an aggressive form of lymphoma unlikely to respond to the targeted treatment ibrutinib.